69640-38-6

69640-38-6 structure

Name: Pentachloropseudilin
Chemical Name: 2,4-Dichloro-6-(3,4,5-trichloro-1H-pyrrol-2-yl)phenol
CAS Number: 69640-38-6
Molecular Formula: C₁₀H₄Cl₅NO
Molecular Weight: 331.41
Catalog: Signaling Pathways Cytoskeleton Myosin
Create Date: 2017-07-14 15:17:21
Modify Date: 2024-01-02 11:30:46
Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC50s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β)-stimulated signaling, with an IC50 of 0.1 to 0.2 μM for TGF-β[1][2].

Name	2,4-Dichloro-6-(3,4,5-trichloro-1H-pyrrol-2-yl)phenol
Synonyms	2xel Pentachloropseudilin

Description	Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC50s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β)-stimulated signaling, with an IC50 of 0.1 to 0.2 μM for TGF-β[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cytoskeleton >> Myosin
In Vitro	Pentachloropseudilin (PClP) inhibits TGF-β-stimulated Smad2/3 phosphorylation and plasminogen activator inhibitor-1 (PAI-1) promoter activation with an IC50 of 0.1 μM in target cells (A549, HepG2, and Mv1Lu cells)[1]. Pentachloropseudilin attenuates TGF-β-stimulated expression of vimentin, N-cadherin, and fibronectin and, thus, blocks TGF-β-induced epithelial to mesenchymal transition (EMT) in these cells. Pentachloropseudilin (0.05 to 1 μΜ; 0-6 hours) pretreatment inhibits TGF-β-mediated (50 or 100 pM) increases in p-Smad2/3 expression to 47% (Mv1Lu) and 79% (A549), respectively[1]. Pentachloropseudilin (0.2 μM) suppresses TGF-β-stimulated cellular responses by attenuating cell-surface expression of the type II TGF-β receptor through accelerating caveolae-mediated internalization followed by primarily lysosome-dependent degradation of the receptor, as demonstrated by sucrose density gradient analysis and immune fluorescence staining[1]. Pentachloropseudilin (200 μM; 24 hours) exhibits and altered cell viability in HUVECs[2].
References	[1]. Chinthalapudi K, et al. Mechanism and specificity of pentachloropseudilin-mediated inhibition of myosin motor activity. J Biol Chem. 2011;286(34):29700-29708. [2]. Chung CL, et al. Pentachloropseudilin Inhibits Transforming Growth Factor-β (TGF-β) Activity by Accelerating Cell-Surface Type II TGF-β Receptor Turnover in Target Cells. Chembiochem. 2018;19(8):851-864. [3]. Cota Teixeira S, et al. Pentachloropseudilin Impairs Angiogenesis by Disrupting the Actin Cytoskeleton, Integrin Trafficking and the Cell Cycle. Chembiochem. 2019;20(18):2390-2401.

Density	1.733g/cm3
Boiling Point	445.9ºC at 760 mmHg
Molecular Formula	C₁₀H₄Cl₅NO
Molecular Weight	331.41
Flash Point	223.5ºC
Exact Mass	328.87400
PSA	36.02000
LogP	5.65430
Index of Refraction	1.672

CHEMICAL IDENTIFICATION

RTECS NUMBER :: SL0537000

CHEMICAL NAME :: Phenol, 2,4-dichloro-6-(3,4,5-trichloro-2-pyrrolyl)-

CAS REGISTRY NUMBER :: 69640-38-6

BEILSTEIN REFERENCE NO. :: 1484123

LAST UPDATED :: 199612

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C10-H4-Cl5-N-O

MOLECULAR WEIGHT :: 331.40

WISWESSER LINE NOTATION :: T5MJ BG CG DG ER BQ CG EG

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5330 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JANTAJ Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo, 141, Japan) V.2-5, 1948-52; V.21- 1968- Volume(issue)/page/year: 32,79-117,1979

Hazard Codes	Xi

69640-34-2

~79%

69640-38-6

Literature: Martin, Rene; Jaeger, Anne; Bohl, Markus; Richter, Sabine; Fedorov, Roman; Manstein, Dietmar J.; Gutzeit, Herwig O.; Knolker, Hans-Joachim Angewandte Chemie - International Edition, 2009 , vol. 48, # 43 p. 8042 - 8046

69640-33-1

69640-38-6

Literature: KINARIS BIOMEDICALS GMBH Patent: US2011/105554 A1, 2011 ;

1158522-08-7	2228926-80-3
2228267-35-2	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4